CHARLOTTESVILLE (CVILLE RIGHT NOW) — Following the announcement by Gov. Glenn Youngkin in July that global pharmaceutical company AstraZeneca would be building a multibillion-dollar plant in Virginia, the Richmond Times-Dispatch reported on Wednesday that Virginia Lawmakers had approved the company’s plan to build the plant in Albemarle County.

The Major Employment Investment Project Approval Commission (MEI) voted unanimously to approve AstraZeneca’s economic development package along with Eli Lilly’s & Co., which plans to build its own manufacturing plant in Goochland County. The reports were further confirmed to Virginia Business by a state official, who stressed that the packages still require approval from the General Assembly.

A source confirmed the matter came before the MEI committee last week, but declined to confirm any other details of the report.

Neither company has publicly confirmed the locations of either plant. AstraZeneca did not respond immediately to Cville Right Now’s request for comment.

Youngkin first made the announcement of AstraZeneca’s commitment to build a plan in Virginia back in July at an event in Washington D.C. Flanked by AstraZeneca CEO Pascal Soriot and other company leadership, as well as White House National Economic Council Director Kevin Hassett, Youngkin expressed excitement over the deal.

“This project will set the standard for the latest technological advancements in pharmaceutical manufacturing, creating hundreds of highly skilled jobs and helping further strengthen the nation’s domestic supply chain,” Youngkin said in a release at the time. “Advanced manufacturing is at the heart of Virginia’s dynamic economy, so I am thrilled that AstraZeneca, one of the world’s leading pharmaceutical companies, plans to make their largest global manufacturing investment here in the Commonwealth.”

At the announcement, AstraZeneca said the project will be its largest single facility investment ever as it plans to invest $50 billion into the United States by 2030. At the time, the exact location of the plant was not announced, but sources told the Richmond Times-Dispatch that Albemarle was selected due to its proximity to the University of Virginia and the Paul and Dianne Manning Institute of Biotechnology. The latter of which will be opened by the University next year in Fontaine Research Park and is led by Mark Esser, a former vice president at AstraZeneca and an alumnus of the UVa School of Medicine.

“AstraZeneca selecting Virginia for this significant biopharmaceutical investment highlights the Commonwealth’s growing reputation as a hub for life sciences innovation,” Virginia Secretary of Commerce and Trade Juan Pablo Segura said at the July announcement. “With our top-tier research institutions, skilled workforce, and commitment to advanced manufacturing, we are well-positioned to support the breakthroughs that improve lives around the world. We welcome the opportunity to partner with global industry leaders who recognize Virginia’s unique strengths.”